EAU Annual Congress

Holmium laser advances help propel progress in BPH, urinary stones

August 05, 2020

Holmium laser lithotripsy with Moses 2.0 is intended to enhance precision and versatility by optimizing laser energy transmission.

Darolutamide efficacy sustained in nonmetastatic CRPC patients with rapid PSA doubling time

July 30, 2020

A subgroup analysis of the pivotal phase 3 ARAMIS trial showed that the efficacy of darolutamide was sustained in patients with a rapid PSA double time.

5-year data sustain water vapor thermal therapy benefit in BPH-related LUTS

July 30, 2020

Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Thulium fiber laser shows efficiency advantage in experimental setting

July 29, 2020

Super-pulsed thulium fiber laser (TFL) has greater efficiency than a holmium:YAG laser, even when using the TFL with a smaller core-diameter fiber, according to preclinical findings.

Algorithm may predict health-related quality of life in patients with urolithiasis

July 28, 2020

The machine learning algorithm incorporates readily available clinical information.

Men on active surveillance for prostate cancer may benefit from Mediterranean diet

July 28, 2020

Mediterranean diet score was modestly associated with time to grade group progression.

Study reveals risk factors for upgrading in active surveillance for prostate cancer

July 27, 2020

“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.

Nephrectomy after immunotherapy can achieve complete response in selected patients

July 27, 2020

A study author said that “the long exposure [to immune checkpoint inhibitor therapy] results in challenging surgery.”

Paclitaxel-hyaluronic acid conjugate induces CR in 75% of patients with bladder CIS

July 24, 2020

Intravesical Oncofid P-B, a conjugate of paclitaxel and hyaluronic acid, is active in patients with carcinoma in situ of the bladder that is not responsive to bacillus Calmette-Guérin.

Pembrolizumab plus nab-paclitaxel active as salvage strategy in urothelial carcinoma

July 24, 2020

Given the efficacy and safety demonstrated, there may be a role going forward for the pembrolizumab/nab-paclitaxel combination in earlier disease stages.